{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:30:43Z","timestamp":1787002243623,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2016.55","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T12:14:36Z","timestamp":1469794476000},"page":"e448-e448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Randomized phase III trial of consolidation therapy with bortezomib\u2013lenalidomide\u2013Dexamethasone (VRd) vs bortezomib\u2013dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen"],"prefix":"10.1038","volume":"6","author":[{"given":"S J","family":"Jacobus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S V","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E A","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N S","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L M","family":"Dreosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Q","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,29]]},"reference":[{"key":"BFbcj201655_CR1","doi-asserted-by":"crossref","unstructured":"Durie BG, Hoering A, Rajkumar SV, Abidi MH, Epstein J, Kahanic SP et al. Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Results of the randomized phase III trial SWOG S0777. Blood (ASH Annual Meeting 177 Abstracts) 2015, 653.","DOI":"10.1182\/blood.V126.23.25.25"},{"key":"BFbcj201655_CR2","unstructured":"National Comprehensive Cancer network (NCCN) Guidelines Version 4. Multiple Myeloma. 2015."},{"key":"BFbcj201655_CR3","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseay JL, Miquel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbcj201655_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbcj201655_CR5","first-page":"181","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life tables. J Royal Stat Soc B 1972; 34: 181\u2013220.","journal-title":"J Royal Stat Soc B"},{"key":"BFbcj201655_CR6","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","volume":"32","author":"H Uno","year":"2014","unstructured":"Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. JCO 2014; 32: 2380\u20132385.","journal-title":"JCO"},{"key":"BFbcj201655_CR7","first-page":"582","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW . Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582\u2013592.","journal-title":"Med Care"},{"key":"BFbcj201655_CR8","first-page":"5381","volume":"16","author":"D Dilts","year":"2010","unstructured":"Dilts D, Cheng S, Crites J, Sandler A, Doroshow J . Phase III clinical trial development: a process of chutes and ladders. CCR 2010; 16: 5381\u20135389.","journal-title":"CCR"},{"key":"BFbcj201655_CR9","first-page":"5557","volume":"16","author":"S Cheng","year":"2010","unstructured":"Cheng S, Dietrich M, Dilts D . A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. CCR 2010; 16: 5557\u20135563.","journal-title":"CCR"},{"key":"BFbcj201655_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","volume":"132","author":"A Smith","year":"2005","unstructured":"Smith A, Wistloff F, Samson D . Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2005; 132: 410\u2013451.","journal-title":"Br J Haematol"},{"key":"BFbcj201655_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/blood-2006-08-036947","volume":"110","author":"P Richardson","year":"2007","unstructured":"Richardson P, Jagannath S, Raje N, Jakubowiak A, Lonial S, Avigan D et al. Lenalidomide, Bortezomib, and Dexamethasone (Rev\/Vel\/Dex) as front-line therapy for patients with multiple myeloma (MM). Preliminary results of a Phase 1\/2 study. Blood 2007; 110: 187.","journal-title":"Blood"},{"key":"BFbcj201655_CR12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V116.21.624.624","volume":"116","author":"M Roussel","year":"2010","unstructured":"Roussel M, Avet-Loiseau H, Moreau P . Frontline therapy with bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by autologous stem cell transplantation, VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma patients: primary results of the IFM 2008 phase II study. Blood 2010; 116: 624.","journal-title":"Blood"},{"key":"BFbcj201655_CR13","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG . Randomized, Multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119: 4375\u20134382.","journal-title":"Blood"},{"key":"BFbcj201655_CR14","doi-asserted-by":"crossref","unstructured":"Weiss M, Gertz MA, Little RF, Rajkumar V, Jacobus SJ, Abonour R et al. Strategies to overcome barriers to accrual (BtA) to NCI-sponsored clinical trials: a project of the NCI-Myeloma Steering Committee Accrual Working Group (NCI-MYSC AWG). ASCO Annu Meet Proc 2013; 31, Abstr 8592.","DOI":"10.1200\/jco.2013.31.15_suppl.8592"},{"key":"BFbcj201655_CR15","unstructured":"Institute of Medicine A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. The National Academies Press: Washington, DC, USA, 2010."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201655.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201655","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201655.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T03:48:57Z","timestamp":1672804137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,29]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7]]}},"alternative-id":["BFbcj201655"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.55","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,29]]},"assertion":[{"value":"29 July 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Stadtmauer has been a consultant for Celgene, Takeda and Amgen. Dr Stewart has received honoraria for consulting from Celgene. Dr Dreosti has received speaker honorarium from Janssen Pharmaceuticals and congress sponsorship from Janssen Pharmaceuticals. Dr Fonseca has received consulting fees from Celgene and Takeda. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}